Use of single-nucleotide polymorphisms and mammographic density plus classic risk factors for breast cancer risk prediction

JAMA Oncology

Volumn 4, Issue 4, 2018, Pages 476-482

  Van Veen, Elke M ^a   Brentnall, Adam R ^b   Byers, Helen ^a   Harkness, Elaine F ^c,d,e   Astley, Susan M ^c,d,e   Sampson, Sarah ^c   Howell, Anthony ^c,e,f   Newman, William G ^a,c,e   Cuzick, Jack ^b   Evans, Gareth R ^a,c,e,f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DENSITY; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; ENGLAND; FEMALE; GENOTYPE; HUMAN; INCIDENCE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MATHEMATICAL MODEL; MIDDLE AGED; POPULATION; PREDICTION; PREVALENCE; QUESTIONNAIRE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR INVASION; TYRER CUZICK RISK MODEL; BREAST; BREAST TUMOR; DIAGNOSTIC IMAGING; DNA MUTATIONAL ANALYSIS; FOLLOW UP; GENETIC SCREENING; GENETICS; MASS SCREENING; PATHOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR;

TUMOR MARKER;

AGED; BIOMARKERS, TUMOR; BREAST; BREAST DENSITY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; ENGLAND; FEMALE; FOLLOW-UP STUDIES; GENETIC TESTING; HUMANS; MASS SCREENING; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 85046491446     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.4881     Document Type: Article

References (26)

1. Eccles SA, Aboagye EO, Ali S, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013;15(5):R92.
2. Michailidou K, Beesley J, Lindstrom S, et al; BOCS; kConFab Investigators; AOCS Group; NBCS; GENICA Network. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47(4):373-380.
3. Kapoor NS, Curcio LD, Blakemore CA, et al. Multigene panel testing detects equal rates of pathogenic BRCA1/2 mutations and has a higher diagnostic yield compared to limited BRCA1/2 analysis alone in patients at risk for hereditary breast cancer. Ann Surg Oncol. 2015;22(10):3282-3288.
4. Thompson ER, Rowley SM, Li N, et al. Panel testing for familial breast cancer: calibrating the tension between research and clinical care. J Clin Oncol. 2016;34(13):1455-1459.
5. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111-1130.
6. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
7. Warwick J, Birke H, Stone J, et al. Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. Breast Cancer Res. 2014;16(5):451.
8. Brentnall AR, Harkness EF, Astley SM, et al. Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Breast Cancer Res. 2015;17(1):147.
9. Brentnall AR, Evans DG, Cuzick J. Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK. Br J Cancer. 2014;110(3):827-828.
10. Evans DG, Warwick J, Astley SM, et al. Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. Cancer Prev Res (Phila). 2012;5(7):943-951.
11. Dite GS, MacInnis RJ, Bickerstaffe A, et al. Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev. 2016; 25(2):359-365.
12. Vachon CM, Pankratz VS, Scott CG, et al. The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst. 2015;107(5):dju397.
13. Evans DG, Astley S, Stavrinos P, et al. Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. Southampton (UK): NIHR Journals Library; 2016 Aug (Programme Grants for Applied Research, No. 4.11). https://www.ncbi.nlm.nih.gov/books/NBK379488/. Accessed December 7, 2017.
14. Turnbull C, Ahmed S, Morrison J, et al; Breast Cancer Susceptibility Collaboration (UK). Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet. 2010; 42(6):504-507.
15. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. 2009;Chapter 2:12.
16. McIntosh ASC, Evans G, Turnbull N, et al. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, clinical guideline [CG164]. https://www.nice.org.uk/Guidance/CG164. Accessed February 15, 2017.
17. Cuzick J, Sestak I, Forbes JF, et al; IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922): 1041-1048.
18. Michailidou K, Hall P, Gonzalez-Neira A, et al; Breast and Ovarian Cancer Susceptibility Collaboration; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); kConFab Investigators; Australian Ovarian Cancer Study Group; GENICA (Gene Environment
19. Interaction and Breast Cancer in Germany) Network. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353-361, e1-e2.
20. Garcia-Closas M, Couch FJ, Lindstrom S, et al; Gene ENvironmental Interaction and breast CAncer (GENICA) Network; kConFab Investigators; Familial Breast Cancer Study (FBCS); Australian Breast Cancer Tissue Bank (ABCTB) Investigators. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013;45(4):392-398, e1-e2.
21. Horne HN, Chung CC, Zhang H, et al; kConFab/AOCS Investigators. Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS One. 2016;11(8):e0160316.
22. Office for National Statistics. International Passenger Survey 3.05b, citizenship by age, UK. https://www.ons.gov.uk/peoplepopulationandcommunity /populationandmigration/internationalmigration /datasets/internationalpassengersurveycitizenship byagetable305b. Accessed November 3, 2017.
23. Office for National Statistics. Local Area Migration Indicators, UK. https://www.ons.gov.uk/peoplepopulationandcommunity /populationandmigration/migrationwithintheuk /datasets /localareamigrationindicatorsunitedkingdom. Accessed November 3, 2017.
24. Irshad A, Leddy R, Ackerman S, et al. Effects of changes in BI-RADS Density Assessment Guidelines (fourth versus fifth edition) on breast density assessment: intra- and interreader agreements and density distribution. AJR Am J Roentgenol. 2016; 207(6):1366-1371.
25. Shieh Y, Hu D, Ma L, et al. Breast cancer risk prediction using a clinical risk model and polygenic risk score. Breast Cancer Res Treat. 2016;159(3):513-525.
26. Evans DM, Visscher PM, Wray NR. Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk. Hum Mol Genet. 2009;18 (18):3525-3531.